|Articles|October 1, 1998

The Treatment of Migraine: A Managed Care Perspective
Volume 4
Issue 10 Suppl

Triptan Use and the Economic Impact of Migraine

Author(s)Jeffrey P. Trotter, MM

Download PDF: Triptan Use and the Economic Impact of Migraine

Articles in this issue

over 27 years ago

Article

Participating Faculty

over 27 years ago

Article

Introduction

over 27 years ago

Article

Etiology and Treatment Options for Migraine Management

over 27 years ago

Article

Current Treatment Strategies for Migraine Disorder

over 27 years ago

Article

The Economic Burden of Migraine: The Role of the Triptans

over 27 years ago

Article

Management of Migraine: Opportunity or Bottomless Pit?

over 27 years ago

Article

CME Quiz

over 27 years ago

Article

Selected Abstracts

over 27 years ago

Article

Bibliography

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Gabriela Samayoa, MD, MPH,Xue Han, PhD,Deborah Freedman, MBA,Lauren Isenman, MPH,Rashmi Patel, MD, PhD

June 12th 2026

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

ByJason Bartock, MD,Adam Green, MD,Raquel Nahra, MD,Amy Bordogna, MD,Amir Davoodi, MD,Jean-Sebastien Rachoin, MD

June 11th 2026

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

ByDana R. Fletcher, PhD,Lisa M. Sandy, MA,Joy Waughtal, MPH,Cole Hoffman, MS,Sylvie Novins-Montague, BA,Patrick Hosokawa, MS,Pamela N. Peterson, MD, MSPH,Larry A. Allen, MD, MPH,Sheana Bull, PhD,P. Michael Ho, MD, PhD

June 10th 2026

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Triptan Use and the Economic Impact of Migraine

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

Social Factors May Match, Outpace Genetic Risk in Disease Prediction

Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk

A Case for SGLT2 Inhibitors in Non-Diabetic CKD: Sandra Chaparro, MD

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Triptan Use and the Economic Impact of Migraine

Articles in this issue

Related Content

The Effect of Medicaid Reimbursement for Psychiatrists on the Health Care Burden of Serious Mental Illness

Association of Travel Nursing With Quality Outcomes in Hospitalized Patients

Cost of Behavioral Messaging Interventions for Cardiovascular Medication Adherence

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Trending on AJMC

Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

Social Factors May Match, Outpace Genetic Risk in Disease Prediction

Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk

A Case for SGLT2 Inhibitors in Non-Diabetic CKD: Sandra Chaparro, MD